

**THE CONSULTANT AND INVESTMENT GROUP COMPANY**

**PUBLIC SHAREHOLDING COMPANY**

**INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**31 MARCH 2024**



**Building a better  
working world**

Ernst & Young Jordan  
P.O. Box 1140  
300 King Abdulla Street  
Amman 11118  
Jordan  
Tel:00962 6 580 0777 /00962 6552 6111  
Fax:00962 6 5538 300  
www.ey.com

**Report on Review of Interim Condensed Consolidated Financial Statements  
To the Board of Directors of The Consultant and Investment Group Company  
Public Shareholding Company  
Amman - Jordan**

**Introduction**

We have reviewed the accompanying interim condensed consolidated financial statements of the Consultant and Investment Group Company - Public Shareholding Company (the “Company”) and its subsidiary (the “Group”) as at 31 March 2024, comprising of the interim condensed consolidated statement of financial position as at 31 March 2024 and the related interim condensed consolidated statements of comprehensive income, interim condensed consolidated statements of changes in equity and interim condensed consolidated statements of cash flows for the three-month period then ended and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard IAS (34) (“Interim Financial Reporting”). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

**Scope of Review**

We conducted our review in accordance with International Standard on Review Engagements (2410) “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS (34).

**ERNST & YOUNG**  
Amman - Jordan

Amman – Jordan  
30 April 2024

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**FOR THE THREE MONTHS PERIOD ENDED 31 MARCH 2024 (UNAUDITED)**

|  | Notes | 31 March<br>2024<br>JD<br>(Unaudited) | 31 December<br>2023<br>JD<br>(Audited) |
|--|-------|---------------------------------------|--|
| <b><u>ASSETS</u></b>                                   |       |                                       |  |
| <b>NON-CURRENT ASSETS -</b>                            |       |                                       |  |
| Property and equipment                                 | 3     | 17,604,625                            | 17,722,841                             |
| Projects under construction                            | 3     | 11,645,106                            | 11,026,329                             |
| Investment properties                                  |       | 2,735,044                             | 2,735,044                              |
| Right-of-use assets                                    |       | 811,587                               | 838,537                                |
| Deferred tax assets                                    | 6     | 548,725                               | 548,725                                |
|  |       | <u>33,345,087</u>                     | <u>32,871,476</u>                      |
| <b>CURRENT ASSETS -</b>                                |       |                                       |  |
| Medicine and medical supplies                          |       | 1,653,498                             | 1,455,679                              |
| Accounts receivable                                    |       | 5,388,912                             | 4,708,305                              |
| Other debit balances                                   |       | 1,130,443                             | 1,173,183                              |
| Checks under collection                                |       | 65,224                                | 50,453                                 |
| Cash-on-hand and bank balances                         | 8     | 363,909                               | 287,314                                |
|  |       | <u>8,601,986</u>                      | <u>7,674,934</u>                       |
| <b>TOTAL ASSETS</b>                                    |       | <u>41,947,073</u>                     | <u>40,546,410</u>                      |
| <b><u>EQUITY AND LIABILITIES</u></b>                   |       |                                       |  |
| <b>SHAREHOLDERS' EQUITY -</b>                          |       |                                       |  |
| Paid-in capital  | 1, 7  | 20,000,000                            | 20,000,000                             |
| Statutory reserve                                      | 7     | 911,074                               | 911,074                                |
| Retained earnings                                      |       | 1,285,766                             | 1,150,618                              |
| <b>NET EQUITY</b>                                      |       | <u>22,196,840</u>                     | <u>22,061,692</u>                      |
| <b>LIABILITIES</b>                                     |       |                                       |  |
| <b>NON-CURRENT LIABILITIES -</b>                       |       |                                       |  |
| Long-term lease liabilities                            |       | 525,000                               | 550,523                                |
| Long-term liabilities against finance lease contracts  | 4     | 9,210,471                             | 9,152,632                              |
| Long-term Murabaha facilities                          | 5     | 1,936,487                             | 96,749                                 |
|  |       | <u>11,671,958</u>                     | <u>9,799,904</u>                       |
| <b>CURRENT LIABILITIES -</b>                           |       |                                       |  |
| Short-term lease liabilities                           |       | 425,574                               | 370,000                                |
| Short-term liabilities against finance lease contracts | 4     | 1,487,964                             | 1,639,306                              |
| Short-term Murabaha facilities                         | 5     | 542,014                               | 264,892                                |
| Contingent liabilities provision                       |       | 1,161,790                             | 1,051,790                              |
| Accounts payable and other credit balances             |       | 4,400,876                             | 5,134,391                              |
| Income tax provision                                   | 6     | 60,057                                | 224,435                                |
|  |       | <u>8,078,275</u>                      | <u>8,684,814</u>                       |
| <b>TOTAL LIABILITIES</b>                               |       | <u>19,750,233</u>                     | <u>18,484,718</u>                      |
| <b>TOTAL EQUITY AND LIABILITIES</b>                    |       | <u>41,947,073</u>                     | <u>40,546,410</u>                      |

The attached notes from 1 to 11 form part of these interim condensed consolidated financial statements

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**FOR THE THREE MONTHS PERIOD ENDED 31 MARCH 2024 (UNAUDITED)**

|   |       | For the three months ended<br>31 March |                    |
|---|-------|--|--------------------|
|   | Notes | 2024                                   | 2023               |
|   |       | JD                                     | JD                 |
| Operating revenues  |       | 4,931,512                              | 4,267,714          |
| Cost of operating revenues  |       | <u>(3,757,543)</u>                     | <u>(3,459,480)</u> |
| <b>Gross profit</b>   |       | 1,173,969                              | 808,234            |
| General and administrative expenses                               |       | (924,999)                              | (931,038)          |
| Finance and lease liabilities costs                               |       | (185,675)                              | (91,579)           |
| Other income, net   |       | <u>137,019</u>                         | <u>37,481</u>      |
| <b>Profit (loss) for the period before income tax</b>             |       | 200,314                                | (176,902)          |
| Income tax  | 6     | <u>(65,166)</u>                        | <u>(7,262)</u>     |
| <b>Profit (loss) for the period</b>                               |       | 135,148                                | (184,164)          |
| Other comprehensive income items                                  |       | <u>-</u>                               | <u>-</u>           |
| <b>Total comprehensive income for the period</b>                  |       | <u>135,148</u>                         | <u>(184,164)</u>   |
|   |       | JD/Fils                                | JD/Fils            |
| <b>Basic and diluted earnings (loss) per share for the period</b> | 11    | <u>0/007</u>                           | <u>(0/009)</u>     |

The attached notes from 1 to 11 form part of these interim condensed consolidated financial statements

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE THREE MONTHS PERIOD ENDED 31 MARCH 2024 (UNAUDITED)**

|  | Paid-in capital<br>JD | Statutory<br>reserve<br>JD | Retained<br>earnings<br>JD | Total<br>JD       |
|--|-----------------------|----------------------------|----------------------------|-------------------|
| <b>For the three months period ended 31 March 2024 -</b> |                       |                            |                            |                   |
| Balance as at 1 January 2024                             | 20,000,000            | 911,074                    | 1,150,618                  | 22,061,692        |
| Total comprehensive income for the period                | -                     | -                          | 135,148                    | 135,148           |
| Balance as at 31 March 2024                              | <u>20,000,000</u>     | <u>911,074</u>             | <u>1,285,766</u>           | <u>22,196,840</u> |
| <b>For the three months period ended 31 March 2023 -</b> |                       |                            |                            |                   |
| Balance as at 1 January 2023                             | 20,000,000            | 793,808                    | 431,338                    | 21,225,146        |
| Total comprehensive income for the period                | -                     | -                          | (184,164)                  | (184,164)         |
| Balance as at 31 March 2023                              | <u>20,000,000</u>     | <u>793,808</u>             | <u>247,174</u>             | <u>21,040,982</u> |

The attached notes from 1 to 11 form part of these interim condensed consolidated financial statements

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE THREE MONTHS PERIOD ENDED 31 MARCH 2024 (UNAUDITED)**

|   | Notes | For the three months ended<br>31 March |                  |
|---|-------|--|------------------|
|   |       | 2024<br>JD                             | 2023<br>JD       |
| <b><u>OPERATING ACTIVITIES</u></b>                        |       |  |                  |
| Profit (loss) for the period before tax                   |       | 200,314                                | (176,902)        |
| <b>Adjustments for:</b>                                   |       |  |                  |
| Finance costs and lease liability interest                |       | 185,675                                | 91,579           |
| Depreciation  | 3     | 288,260                                | 275,592          |
| Depreciation on right-of-use assets                       |       | 77,946                                 | 83,277           |
| Provision for contingent liabilities                      |       | 110,000                                | 100,000          |
| Provision for employees' vacations                        |       | 26,257                                 | 2,852            |
| Provision for end-of-service indemnity                    |       | 8,629                                  | 6,771            |
| <b>Working capital changes:</b>                           |       |  |                  |
| Medicine and medical supplies                             |       | (197,819)                              | 16,348           |
| Accounts receivable                                       |       | (680,607)                              | (712,341)        |
| Cheques under collection                                  |       | (14,771)                               | (29,999)         |
| Other debit balances                                      |       | 42,740                                 | 22,007           |
| Accounts payable and other credit balances                |       | (719,145)                              | 1,018,846        |
| Income tax paid   | 6     | (229,544)                              | (19,950)         |
| Provision for contingent liabilities paid                 |       | -                                      | (127,794)        |
| Provision for employees' vacations paid                   |       | (4,915)                                | -                |
| Provision for end of service indemnity paid               |       | -                                      | (9,793)          |
| <b>Net cash flows (used in) from operating activities</b> |       | <b>(906,980)</b>                       | <b>540,493</b>   |
| <b><u>INVESTING ACTIVITIES</u></b>                        |       |  |                  |
| Purchases of property and equipment                       | 3     | (170,044)                              | (56,312)         |
| Projects under construction                               | 3     | (618,777)                              | (337,186)        |
| <b>Net cash flows used in investing activities</b>        |       | <b>(788,821)</b>                       | <b>(393,498)</b> |
| <b><u>FINANCING ACTIVITIES</u></b>                        |       |  |                  |
| Liabilities against finance lease contracts               |       | (93,503)                               | 27,531           |
| Murabaha facilities                                       |       | 2,116,860                              | -                |
| Finance costs and lease liabilities interests paid        |       | (234,713)                              | (63,288)         |
| Lease liabilities paid                                    |       | (33,415)                               | (143,495)        |
| <b>Net cash flows from (used in) financing activities</b> |       | <b>1,755,229</b>                       | <b>(179,252)</b> |
| Net increase (decrease) in cash and cash equivalents      |       | 59,428                                 | (32,257)         |
| Cash and cash equivalents at the beginning of the period  |       | 304,481                                | 174,919          |
| <b>Cash and cash equivalents at the end of the period</b> | 8     | <b>363,909</b>                         | <b>142,662</b>   |

The attached notes from 1 to 11 form part of these interim condensed consolidated financial statements

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**(1) GENERAL**

The Consultant and Investments Group Company (Istishari Hospital) was established and registered on 7 November 1995, as a Public Shareholding Company. The Company's paid-in capital is JD 8,000,000. It was increased in prior years in phases to become JD 20,000,000 as at 31 March 2024. The Company's offices are located in Wadi Saqra, P.O Box 840431 Amman 11184 The Hashemite Kingdom of Jordan.

The principal activities of the Company are industrial construction, commercial agencies, investment in commercial and financial projects, establishment and management of health and construction projects, real estate, residential, urban or industrial, commercial markets of all kinds and related services.

The interim condensed consolidated financial statements were approved by the Board of Directors on 28 April 2024.

**(2) BASIS OF PREPARATION AND ACCOUNTING POLICIES**

**Basis of preparation –**

The interim condensed consolidated financial statements as at 31 March 2024 have been prepared in accordance with International Accounting Standard (34), ("Interim Financial Reporting").

The interim condensed consolidated financial statements are presented in Jordanian Dinars, which is the functional currency of the Group.

The interim condensed consolidated financial statements do not contain all information and disclosures that are required by the International Financial Reporting Standards (IFRSs) and should be read in conjunction with the Group's annual report as at 31 December 2023. In addition, the results of the three-month period ended 31 March 2024 are not necessarily indicative of the result that may be expected for the financial year ending 31 December 2024.

The interim condensed consolidated financial statements comprise the financial statements of the Company and the following subsidiary:

|   | Capital | Nature of activity   | Ownership Percentage |                     |
|---|---------|--|----------------------|---------------------|
|   | JD      |  | 31 March<br>2024     | 31 December<br>2023 |
|   |         |  | %                    | %                   |
| Al Motamaizah for Hospital<br>Management Co | 15,000  | Hospital services and<br>import of medical devices<br>and supplies | 100                  | 100                 |

### **CHANGES IN ACCOUNTING POLICIES**

The accounting policies used in the preparation of the interim condensed consolidated financial statements are consistent with those used in the preparation of the annual consolidated financial statements for the year ended 31 December 2023 except for the adoption of new amendments on the standards effective as at 1 January 2024 shown below:

#### **Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7**

In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.

The Group is not required to provide the disclosures in any interim periods in the year of initial application of the amendments. The amendments are not expected to have a material impact on the Group's interim condensed consolidated financial statements.

#### **Amendments to IFRS 16: Lease Liability in a Sale and Leaseback**

In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognize any amount of the gain or loss that relates to the right of use it retains.

The amendments had no material impact on the Group's interim condensed consolidated financial statements.

#### **Amendments to IAS 1: Classification of Liabilities as Current or Non-current**

In January 2020 and October 2022, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:

- What is meant by a right to defer settlement
- That a right to defer must exist at the end of the reporting period
- That classification is unaffected by the likelihood that an entity will exercise its deferral right
- That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification

In addition, a requirement has been introduced whereby an entity must disclose when a liability arising from a loan agreement is classified as non-current and the entity's right to defer settlement is contingent on compliance with future covenants within twelve months.

The amendments had no material impact on the Group's interim condensed consolidated financial statements.



**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

**(3) PROPERTY, EQUIPMENT AND PROJECTS UNDER CONSTRUCTION**

**Property and Equipment:**

During the three-month period ended 31 March 2024, the Group purchased property and equipment at a cost of JD 170,044 (31 March 2023: JD 56,312). The depreciation amounted to JD 288,260 for the three-months ended 31 March 2024 (31 March 2023: JD 275,592).

**Projects Under Construction:**

This account represents the expansion project of the main building of the hospital. Additions to projects under construction during the three-months period ended 31 March 2024 were amounted to JD 618,777 (31 March 2023: JD 337,186).

**(4) LIABILITIES AGAINST FINANCE LEASE CONTRACTS**

This item represents liabilities against finance lease contracts granted to the Group by the International Arab Islamic Bank:

|                                   | 31 March 2024 (unaudited) |           |            | 31 December 2023 (audited) |           |            |
|-----------------------------------|---------------------------|-----------|------------|----------------------------|-----------|------------|
|                                   | Short-term                | Long-term | Total      | Short-term                 | Long-term | Total      |
|                                   | JD                        | JD        | JD         | JD                         | JD        | JD         |
| Solar energy project *            | 234,849                   | 748,726   | 983,575    | 254,356                    | 807,573   | 1,061,929  |
| Hospital expansion project **     | 1,038,643                 | 3,426,219 | 4,464,862  | 1,170,478                  | 3,183,351 | 4,353,829  |
| Land purchase ***                 | 261,911                   | 5,040,479 | 5,302,390  | 261,911                    | 5,182,888 | 5,444,799  |
|                                   | 1,535,403                 | 9,215,424 | 10,750,827 | 1,686,745                  | 9,173,812 | 10,860,557 |
| Less: Land relinquishment fees*** | (47,439)                  | (4,953)   | (52,392)   | (47,439)                   | (21,180)  | (68,619)   |
| Total                             | 1,487,964                 | 9,210,471 | 10,698,435 | 1,639,306                  | 9,152,632 | 10,791,938 |

\* The Group signed a financial lease agreement on 18 November 2018 to finance a solar energy project with a total value of JD 2,490,750. The lease yield rate was 2.5% annually, of which to be paid in 109 monthly instalments divided over 9 years of JD 22,851 per month. The financing was rescheduled in 2021 that the final instalment due on 18 August 2028.

\*\* The Group signed manufacturing contracts 5 September 2019 for the expansion of the fourth and fifth floors of the Istishari Hospital with a total value of JD 1,694,812. An annual manufacturing margin of 2.36% was to be repaid on 48 monthly instalments.

\*\*\* This item includes liabilities related to financial leasing contracts for the purchase of land as detailed below:

- 1) The Group signed a financial lease agreement 28 July 2016 to finance the purchase of land no. (1284) from the International Arabic Islamic Bank. The Bank acquired the land and then released it to the Group. As a result, the Group incurred transfer fees of JD 426,951 which were paid to the Amman Land Registry and recorded as a liability to be amortized over the life of the facility.

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

The lease term is set at 108 months over 9 years, paid monthly from 31 August 2017. The monthly instalment was amounted to JD 55,931. The financing was rescheduled, and the monthly instalment was amounted to JD 50,691 for a year from 31 May 2022. Also, the financing was rescheduled, so the monthly instalment was amounted to JD 51,872 for a one year from 31 May 2023. The yield rate for the first year was 6.5% of the principal financing amount, while the variable margin for the first year was 1%.

- 2) During 2022, the Group signed financial leasing agreements to purchase two plots of land No. 954 and 1028 in Wadi Saqra Basin No. 18 with the Islamic International Arab Bank, provided that the lease period is 120 months divided into 10 years, and to be paid monthly starting from 30 November 2023. The rate of the return for the first year was 6.2% from the original financing value.

The Group's liabilities under the financial lease contracts are secured by the lessor's ownership of the leased assets.

The annual payments and the finance installments due dates are as follows:

| Year                             | Amount<br>JD      |
|----------------------------------|-------------------|
| 1 April 2024 until 31 March 2025 | 1,535,403         |
| 1 April 2025 until 31 March 2026 | 1,746,472         |
| 1 April 2026 until 31 March 2027 | 1,671,499         |
| 1 April 2027 until 31 March 2028 | 1,707,447         |
| 2028 and after                   | 4,090,006         |
|                                  | <u>10,750,827</u> |

**(5) MURABAHA FACILITIES**

|                             | 31 March 2024 (unaudited) |                  |                  | 31 December 2023 (audited) |               |                |
|-----------------------------|---------------------------|------------------|------------------|----------------------------|---------------|----------------|
|                             | Short-term                | Long-term        | Total            | Short-term                 | Long-term     | Total          |
|                             | JD                        | JD               | JD               | JD                         | JD            | JD             |
| Murabaha finance facilities | 542,014                   | 1,936,487        | 2,478,501        | 264,892                    | 96,749        | 361,641        |
|                             | <u>542,014</u>            | <u>1,936,487</u> | <u>2,478,501</u> | <u>264,892</u>             | <u>96,749</u> | <u>361,641</u> |

This item represents facilities granted to the Group from the International Arabic Islamic Bank as the Group signed in 2023 Murabaha financing agreements with the International Arabic Islamic Bank with a ceiling up to JD 1,000,000 at a Murabaha rate of 6.8% to finance the purchase of medications. These facilities are repaid in monthly instalments. The first payment was due on 1 February 2024, and the final payment is due on 21 May 2025.

The Group signed a restricted investment Wakala agreement with the International Arabic Islamic Bank on 3 March 2024 for financing purposes for an amount of JD 2,100,000 at a Murabaha rate of 10.08%. The first payment is due on 18 August 2024 for a portion of the facility amounted to JD 300,000 paid over 12 monthly installments as the Group has a grace period for the remaining amount of JD 1,800,000. The payments schedule will be agreed upon the completion of the payment of the first installment.

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

**(6) INCOME TAX**

Income tax provision for the periods ended at 31 March 2024 and 2023 was calculated in accordance with the Income Tax Law No. (34) of 2014 and its amendments. The income tax rate for the Group is 20% in addition to a 1% National Contribution tax.

**Tax Returns:**

**The Consultant and Investment Group Company**

The Income Tax and Sales Department audited tax returns for the years between 2016 and 2020 and the Company reached a final settlement with the Income and Sales Tax Department up to the year 2020. During 2021, the Income Tax and Sales Department referred to the declarations for the above-mentioned years and issued a preliminary decision for JD 2.3 million of claims against the Group.

The Group's management objected to the decision and filed a lawsuit against the Income and Sales Tax Department, and the judgment in the case is still pending at the first instance court. The Income and Sales Tax Department audited the tax returns of the years 2021 and 2022 and the Company reached a final settlement with the Income and Sales Tax Department up to the year 2022. The Company filed its tax return for the Income and Sales Tax Department for the year 2023, The Income and Sales Tax Department did not review the Company's accounting records up to the date of these interim condensed consolidated financial statements. In the opinion of the management and their tax consultant, the provision recognized by the Group is sufficient.

**Al Motamaizah for Hospital Management Co (Subsidiary)**

The Company reached a final settlement with the Income and Sales Tax Department up to the year 2022.

Movement on income tax provision is as follows:

|                                       | 31 March<br>2024<br>JD<br>(Unaudited) | 31 December<br>2023<br>JD<br>(Audited) |
|---------------------------------------|---------------------------------------|--|
| Beginning balance for the period/year | 224,435                               | 528,308                                |
| Income tax for the period/year        | 65,166                                | 187,654                                |
| Income tax paid for the period/year   | (229,544)                             | (491,527)                              |
| Ending balance for the period/year    | 60,057                                | 224,435                                |

Movement on deferred tax assets is as follows:

|  | 31 March<br>2024<br>JD<br>(Unaudited) | 31 December<br>2023<br>JD<br>(Audited) |
|--|---------------------------------------|--|
| Balance as at the beginning of the period/year | 548,725                               | 697,181                                |
| Added during the period/year                   | -                                     | 4,394                                  |
| Released during the period/year                | -                                     | (152,850)                              |
| Balance as at the end of the period/year       | 548,725                               | 548,725                                |

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

---

**(7) EQUITY**

**Paid in Capital -**

The authorized and paid-in capital amounted to JD 20,000,000 at par value of JD 1 each.

**Statutory reserve -**

The accumulated amounts in this account represent appropriations of 10% of annual profit before tax and is not available for distribution to shareholders. Statutory reserve should not exceed 25% of the Company's paid in capital.

**(8) CASH AND BANK BALANCES**

Cash and cash equivalent in the interim condensed consolidated statement of financial position is as follows:

|               | 31 March<br>2024 | 31 December<br>2023 |
|---------------|------------------|---------------------|
|               | JD               | JD                  |
|               | (Unaudited)      | (Audited)           |
| Cash-on-hand  | 119,052          | 43,651              |
| Bank balances | 244,857          | 243,663             |
|               | <u>363,909</u>   | <u>287,314</u>      |

For the purpose of interim condensed consolidated statement of cashflows, the details of cash and cash equivalents are as follows:

|               | 31 March<br>2024 | 31 March<br>2023 |
|---------------|------------------|------------------|
|               | JD               | JD               |
|               | (Unaudited)      | (Unaudited)      |
| Cash-on-hand  | 119,052          | 71,315           |
| Bank balances | 244,857          | 71,347           |
|               | <u>363,909</u>   | <u>142,662</u>   |

**THE CONSULTANT AND INVESTMENT GROUP COMPANY - PUBLIC SHAREHOLDING COMPANY**  
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**31 MARCH 2024 (UNAUDITED)**

**(9) RELATED PARTY TRANSACTIONS**

Related party transactions represent transactions with the subsidiary, major shareholders, directors and key management personnel of the Group and the companies which they are major shareholders in. Pricing policies and terms of the transactions with related parties are approved by the Group's management.

The following is a summary of compensations (salaries, allowances and other benefits) of key management personnel of the Group:

|  | 31 March<br>2024  | 31 March<br>2023  |
|--|-------------------|-------------------|
|  | JD<br>(Unaudited) | JD<br>(Unaudited) |
| Salaries and other benefits of key management personal | 46,500            | 46,500            |

**(10) CONTINGENT LIABILITIES**

**Letters of guarantees –**

As at the interim condensed consolidated financial statements date, the Group has outstanding letters of guarantees with an amount of JD 94,038 as at 31 March 2024 (31 December 2023: JD 84,038) against cash margins with an amount of JD 13,906 (2023: JD 12,406).

**Legal claims against the Group –**

In addition to what is disclosed in note (6) regarding the decision to impose an additional income tax on the Group for the years between 2016-2020 and its related litigation where the Group has recorded a provision against this claim, the Group is defendant in a number of lawsuits in the ordinary course of business with an amount of JD 93,382 (31 December 2023: JD 93,382). The Group management and its legal counsel believe that the provision taken against these is adequate to meet any obligations that may arise and no need to book additional provision against these lawsuits.

**(11) BASIC AND DILUTED EARNINGS (LOSS) PER SHARE**

|  | For the three months ended 31<br>March |             |
|--|--|-------------|
|  | 2024                                   | 2023        |
|  | (Unaudited)                            | (Unaudited) |
| Profit (loss) for the period (JD)                          | 135,148                                | (184,164)   |
| Weighted average number of shares (Share)                  | 20,000,000                             | 20,000,000  |
|  | JD/Fils                                | JD/Fils     |
| Basic and diluted earnings (loss) per share for the period | 0/007                                  | (0/009)     |